SCHEMBL733779

SCHEMBL733779

O=C1CCN(c2cccc(OC(F)(F)F)c2)CCN1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.48
DHFR P00374 1/20 0.46
ADRB1 P08588 1/20 0.43
PIM1 P11309 1/20 0.43
MLYCD O95822 1/20 0.43
HTR3E A5X5Y0 1/20 0.43
HTR3B O95264 1/20 0.43
ALDH1A1 P00352 1/20 0.43
HTR1D P28221 1/20 0.43
HTR2C P28335 1/20 0.43
HTR3A P46098 1/20 0.43
HTR3D Q70Z44 1/20 0.43
HTR3C Q8WXA8 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
FFAR4 Q5NUL3 1/20 0.42
MAPT P10636 1/20 0.42
THRB P10828 1/20 0.42
SLC5A1 P13866 2/20 0.41
CHRM4 P08173 4/20 0.41
DRD2 P14416 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17893529 0.83 NOTUM (0.54) NOTUMDHFRMLYCDFFAR4CHRM4
SCHEMBL1735099 0.82 ADRB1 (0.64) NOTUMDHFRADRB1PIM1MLYCD
SCHEMBL735432 0.81 ALDH1A1 (0.67) HTR3EHTR3BALDH1A1HTR1DHTR2C
SCHEMBL20956923 0.78 DRD2 (0.49) NOTUMDHFRPIM1DRD2DRD3
SCHEMBL2439728 0.73 NOTUM (0.50) NOTUMDHFRMLYCDFFAR4DRD2
SCHEMBL2300499 0.73 DHFR (0.55) NOTUMDHFRPIM1MLYCDFFAR4
SCHEMBL28195870 0.73 PRKDC (0.56) NOTUMDHFRPIM1MLYCDFFAR4
SCHEMBL12968842 0.73 ADRA2C (0.56) NOTUMDHFRPIM1MLYCDALDH1A1
SCHEMBL8106701 0.72 NOTUM (0.55) NOTUMDHFRADRB1PIM1MLYCD
SCHEMBL734450 0.72 NOTUM (0.44) NOTUMSLC5A1DRD2DRD3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138175-B2 Heterocyclyl compounds HOFFMANN-LA ROCHE INC. (US) 2012-03-20 US disclosed
EP-2321285-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-La Roche AG (CH) 2011-05-18 EP disclosed
WO-2010012619-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2010-02-04 WO disclosed
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS CCR2, CCR3, CCR5 NOTUM 4344/4885DHFR 905/4885ADRB1 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.